The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Abstract
BACKGROUND GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival and overall survival with sugemalimab, a PD-L1 inhibitor, plus chemotherapy versus placebo plus chemotherapy. We report the 4-year outcomes from this study. METHODS This randomised, double-blind, phase 3 trial was conducted across 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years; had treatment-naive, histologically or cytologically confirmed stage IV NSCLC, irrespective of PD-L1 expression levels; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomised (2:1) by investigators using an interactive web response or voice response system via permuted blocks (block sizes of three or six, randomised within each stratum). Patients received histology-specific platinum-based chemotherapy combined with either sugemalimab (1200 mg; sugemalimab group) or placebo (placebo group) for up to four cycles, followed by for up to 35 cycles of maintenance therapy with sugemalimab alone for patients with squamous NSCLC and sugemalimab plus pemetrexed for patients with non-squamous NSCLC in the sugemalimab group, or placebo for patients with squamous NSCLC and placebo plus pemetrexed for patients with non-squamous NSCLC in the placebo group, administered intravenously. Treatment beyond 35 cycles was permitt…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Self-citationNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01989 · Cited by 733
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.028 · Cited by 599
Self-citationNovello, S., Kowalski, D. M., Luft, A., Gümüş, M., Vicente, D., Mazières, J., Rodríguez-Cid, J., Tafreshi, A., Cheng, Y., Lee, K. H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01990 · Cited by 556
Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463
Cited by
Liu, Y., An, T., Que, Z., Luo, B., Shi, W., Zhou, Y., & Tian, J. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00302-4 · Cited by 6
“The recent emergence of immune checkpoint inhibitors (ICIs), particularly programmed death-1/ programmed death-ligand 1 (PD-1/PD-L1) inhibitors, has heralded a paradigm shift in the therapeutic landscape of NSCLC [2].”
Self-citationTumor-infiltrating lymphocytes in NSCLC: from immune surveillance to immunotherapy
Xue, H., Fan, Y., Li, Y., Zhao, Q., Zhang, X., Zhao, P., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610998 · Cited by 9
Self-citationFederico, A. D., Compagno, S., Mantuano, F., Stumpo, S., Giglio, A. D., Pecci, F., Alessi, J. V., Wang, X., Sperandi, F., Melotti, B., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.1548 · Cited by 6
Resuli, B., Kauffmann-Guerrero, D. E., Lasso, M. N. A., Behr, J., & Tufman, A. (2025) · Diagnostics · doi:10.3390/diagnostics15151937 · Cited by 5
“Sugemalimab (Zhou et al., 2022) reported a PFS HR of 0.49 [40]; camrelizumab in CameL-sq achieved 0.37 [38]; and atezolizumab-based combinations in IMpower130, 132, and 150 showed HRs of 0.64, 0.60, and 0.62, respectively [19,31,32].”
InfluentialChueh, C., Huang, W., Hong, M.-Y., Tsai, Y., Chiang, N., & Chen, H. (2025) · Cancers · doi:10.3390/cancers17193171 · Cited by 3
“…inhibitor, acts on a different component of the PD-1/PD-L1 signaling pathway from other inhibitors and has demonstrated promising results in advanced non-small cell lung cancer [13–15], esophageal squamous cell carcinoma [16], and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma [17].”
Metadata
- Authors
- Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., Zhuang, W., Cui, J., Chen, X., Lu, Y., Shen, H., Hu, C., Liu, J., Liu, Y., Wang, M., Li, X., Sun, P., Shu, Y., Zhou, J., Li, J., Gu, K., Wang, C., Zhao, H., Zhang, Y., Liu, C., Yang, H., Zhang, X., Ma, R., Li, L., Liang, L., Li, M., Wang, J., Wang, Q., Wang, B., Dai, H., Shi, Q., & Yang, J.
- Affiliations
- Tongji University (CN)
- Peking University Cancer Hospital (CN)
- Jinan Central Hospital (CN)
- University of Science and Technology of China (CN)
- Zhengzhou University (CN)
- China Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Sichuan Cancer Hospital (CN)
- Fudan University (CN)
- Hunan Cancer Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- First Hospital of Jilin University (CN)
- Westlake University (CN)
- Sichuan University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Second Xiangya Hospital of Central South University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- First Hospital of China Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Yuhuangding Hospital (CN)
- Jiangsu Province Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Liuzhou General Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Xinjiang Medical University (CN)
- Suzhou Municipal Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Beijing Hospital (CN)
- Peking University Third Hospital (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- CStone Pharmaceuticals (China) (CN)
- Corresponding author
- Zhou, Caicun
- ORCID
- Zhou, Caicun
- Wang, Ziping
- Sun, Meili
- Ma, Zhiyong
- Wu, Rong
- Yu, Yan
- Yao, Wenxiu
- Chen, Jianhua
- Zhuang, Wu
- Cui, Jiuwei
- Chen, Xueqin
- Lu, You
- Shen, Hong
- Hu, Chunhong
- Liu, Jiwei
- Liu, Yunpeng
- Wang, Mengzhao
- Li, Xingya
- Sun, Ping
- Shu, Yongqian
- Zhou, Jianying
- Gu, Kangsheng
- Wang, Changli
- Zhao, Hui
- Liu, Chunling
- Yang, Hui
- Zhang, Xiaochun
- Ma, Rui
- Li, Lin
- Liang, Li
- Li, Man
- Wang, Jingru
- Wang, Qiang
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2025-07
- Volume
- 26
- Issue
- 7
- Pages
- 887-897
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4411265566
- Cited by
- 23
- References
- 24
- Citations by year
- 2026: 17 · 2025: 6
- FWCI
- 15.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sugemalimab, PD-L1 inhibitors, metastatic non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, long-term outcomes, progression-free survival, overall survival, maintenance therapy, squamous NSCLC, non-squamous non-small cell lung cancer, immune checkpoint inhibitors, treatment safety, adverse events
- MeSH terms
- Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(25)00198-6
- The paper
- Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., Zhuang, W., Cui, J., Chen, X., Lu, Y., Shen, H., Hu, C., Liu, J., Liu, Y., Wang, M., . . . Yang, J. (2025). Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(25)00198-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.